612 related articles for article (PubMed ID: 25456318)
1. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
7. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
9. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
13. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
15. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma.
Sutton LM; Cao D; Sarode V; Molberg KH; Torgbe K; Haley B; Peng Y
Am J Clin Pathol; 2012 Oct; 138(4):511-6. PubMed ID: 23010705
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J
Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
19. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
Teoh PY; Tan GC; Mahsin H; Wong YP
Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]